Free Trial
OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis

Tribute Pharmaceuticals Canada logo

About Tribute Pharmaceuticals Canada Stock (OTCMKTS:TBUFF)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
50,100 shs
Average Volume
71,826 shs
Market Capitalization
$105.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

Receive TBUFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tribute Pharmaceuticals Canada and its competitors with MarketBeat's FREE daily newsletter.

TBUFF Stock News Headlines

Valeo Pharma Inc. (VPHIF)
[INSIDE] Elon’s Next Move Could Send This AI Stock Soaring
Missed Nvidia? This Under-the-Radar AI Stock Could Be Next Musk's AI empire is just beginning — and one overlooked company could be at the center of it all. We reveal everything in this exclusive Memorial Day webinar.
See More Headlines

TBUFF Stock Analysis - Frequently Asked Questions

Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) posted its quarterly earnings results on Monday, March, 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.01. The company earned $2.90 million during the quarter.

Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/31/2014
Today
5/23/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:TBUFF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$105.76 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (OTCMKTS:TBUFF) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners